CTLA4 and non-small cell lung carcinoma: Immunotherapy is a target therapy that attacks immune checkpoint pathways, which includes the blockade of the inhibitory receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), and its ligand, PD-L1, and has altered the management of NSCLC over the last 10 years [40].